Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%.
Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%. Barron's
Covered in this story
What has happened since
- Biogen is down 0.2% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Biogen
- BMO Capital Markets: $229 → $220 by Oct 2027 · Market Perform via Investing.com
- Wolfe Research: $216 → $300 by Sep 2027 · Outperform via Yahoo Finance
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from Barron's's public RSS feed. The full reporting belongs to Barron's — please read it on their site.